Evidence map›Paper›PMID 42819059›Full record

ArticleFrontiers in immunology2026

Case Report: The first Mainland Chinese case of

Xiang Gu, Jian Guo, Lei Li, Yi Xia, Xiaohui Lv, Bing Li

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiang GuDepartment of Respiratory and Critical Care Medicine, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Jian GuoDepartment of Respiratory and Critical Care Medicine, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Lei LiDepartment of Respiratory and Critical Care Medicine, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Yi XiaDepartment of Radiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Xiaohui LvDepartment of Respiratory and Critical Care Medicine, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Bing LiDepartment of Respiratory and Critical Care Medicine, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) haploinsufficiency with autoimmune infiltration (CHAI) is an autosomal dominant condition featuring both immunodeficiency and autoimmunity. We describe the first published mainland Chinese patient harboring the heterozygous CTLA4 c.529dupT frameshift variant. While multiple CHAI cases have been documented in mainland China, this specific variant has not been reported in this population to date. The patient developed recurrent thrombocytopenia, recurrent respiratory infections and hypogammaglobulinemia at age 2. She was diagnosed with immune thrombocytopenia (ITP) at age 15. The disease subsequently progressed to Evans syndrome, alongside complications including chronic diarrhea, cerebral vasculitis, biliary tract infection and interstitial pneumonia. She received standard anti-infective therapy, combined glucocorticoids and immunosuppressants, as well as intravenous immunoglobulin (IVIG) replacement; however, these interventions yielded only limited and temporary benefits. After 38 years of disease progression, a primary immunodeficiency was suspected. Whole-exome sequencing (WES) verified the diagnosis of CHAI. Treatment with sirolimus led to amelioration of infection and diarrheal symptoms. This case exhibited phenotypic differences from prior patients carrying the identical variant. Our observations expand the known phenotypic spectrum of this variant and offer clinical references for the management and genetic testing of patients presenting with early-onset multisystem autoimmunity and immunodeficiency.

Indexed as

CTLA-4 AntigenHaploinsufficiencyImmunologic Deficiency SyndromesAdolescentChinaDelayed DiagnosisEast Asian PeopleExome SequencingFemaleFrameshift MutationHumansMiddle AgedPurpura, Thrombocytopenic, IdiopathicCTLA-4 AntigenCTLA4 protein, humanCTLA4 haploinsufficiencyhypogammaglobulinemiaphenotypic heterogeneitysirolimuswhole−exome sequencing

Identifiers

PMID42819059
PMCPMC13623563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.